Joel R Lexchin (Joel Lexchin)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 64

Top Venues

BMJ open

International journal of health policy and management

International journal of social determinants of health and health services

PloS one

University Health Network

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University Health Network Sep 01 1988

Canada

Emergency physician :: Emergency Department

York University Jul 01 2001 - Jun 30 2016

Canada

Professor :: School of Health Policy and Management

Publications

Joel R Lexchin
Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study. Journal of general internal medicine (2024)
Joel R Lexchin, Blue Miaoran Dong, Aravind Ramanathan, Marc-André Gagnon
Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials. International journal of health policy and management 13 (2024)
Joel R Lexchin
Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap". International journal of health policy and management 13 (2024)
Joel R Lexchin, Blue Miaoran Dong, Aravind Ramanathan, Marc-André Gagnon
Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials. International journal of health policy and management 13 (2024)
Brigitte Tenni, Joel R Lexchin, Chutima Akaleephan, Chalermsak Kittitrakul, Deborah Gleeson
The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program. Globalization and health 20 (1) (2024)
Joel R Lexchin
Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap". International journal of health policy and management 13 (2024)
David Benjamin Menkes, Barbara J Mintzes, Joel R Lexchin
Direct-to-consumer advertising: a modifiable driver of overdiagnosis and overtreatment. BMJ evidence-based medicine (2024)
Joel R Lexchin
Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study. Journal of general internal medicine 39 (7) (2024)
Brigitte Tenni, Joel R Lexchin, Chutima Akaleephan, Chalermsak Kittitrakul, Deborah Gleeson
The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program. Globalization and health 20 (1) (2024)
Joel R Lexchin
Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study. Journal of general internal medicine 39 (7) (2024)
Brigitte Tenni, Joel R Lexchin, Chutima Akaleephan, Chalermsak Kittitrakul, Deborah Gleeson
The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program. Globalization and health 20 (1) (2024)
Brigitte Tenni, Joel R Lexchin, Sovath Phin, Deborah Gleeson
Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? International journal of social determinants of health and health services (2024)
Brigitte Tenni, Joel R Lexchin, Sovath Phin, Deborah Gleeson
Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? International journal of social determinants of health and health services 54 (3) (2024)
Joel R Lexchin
Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study. Journal of general internal medicine 39 (7) (2024)
Joel R Lexchin
Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study. Journal of general internal medicine 39 (7) (2024)
Joel R Lexchin, Blue Miaoran Dong, Aravind Ramanathan, Marc-André Gagnon
Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials. International journal of health policy and management 13 (2024)
Brigitte Tenni, Joel R Lexchin, Sovath Phin, Deborah Gleeson
Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? International journal of social determinants of health and health services 54 (3) (2024)
Brigitte Tenni, Joel R Lexchin, Sovath Phin, Deborah Gleeson
Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? International journal of social determinants of health and health services 54 (3) (2024)
Brigitte Tenni, Joel R Lexchin, Sovath Phin, Deborah Gleeson
Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia? International journal of social determinants of health and health services (2024)
Joel R Lexchin
Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study. PloS one 19 (8) (2024)
Joel R Lexchin
Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study. PloS one 19 (8) (2024)
Brigitte Tenni, Joel R Lexchin, Chutima Akaleephan, Chalermsak Kittitrakul, Deborah Gleeson
The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program. Globalization and health 20 (1) (2024)
Joel R Lexchin, Barbara J Mintzes
Semaglutide: a new drug for the treatment of obesity. Drug and therapeutics bulletin (2023)
Zheng Zhu, Quan Wang, Qiang Sun, Joel R Lexchin, Li Yang
Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ global health 8 (7) (2023)
Joel R Lexchin
New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis. PloS one 18 (6) (2023)
Joel R Lexchin
Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada. International journal of social determinants of health and health services (2023)
Joel R Lexchin
Prediction of therapeutic value of new drugs approved by health Canada from 2011-2020: A cross-sectional study. JRSM open 14 (5) (2023)
Lindsay Hedden, Sarah Spencer, Sara Allin, Damien Contandriopoulos, Frank Gavin, Agnes Grudniewicz, Miriam Ruth Lavergne, Chad Leaver, Joel R Lexchin, Madeleine McKay, Maria Mathews, Rita K McCracken, Kimberlyn McGrail, Karen S Palmer, Marie-Eve Poitras, David Rudoler, Sheryl Spithoff, Meredith Vanstone
For health or for profit? Understanding how private financing and for-profit delivery operate within Canadian healthcare (4H|4P): protocol for a multimethod knowledge mobilisation research project. BMJ open 13 (8) (2023)
Joel R Lexchin
Canada and the pharmaceutical industry in the time of COVID-19. International journal of social determinants of health and health services (2023)
Joel R Lexchin
Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study. JRSM open 13 (7) (2022)
Joel R Lexchin
Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study. Journal of general internal medicine 37 (16) (2022)
Joel R Lexchin
Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study. PloS one 17 (10) (2022)
Joel R Lexchin
After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada. International journal of health services : planning, administration, evaluation 52 (3) (2022)
Joel R Lexchin, Sharon Batt, Devorah Goldberg, Adrienne Shnier
National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. BMJ open 12 (3) (2022)
Donald W Light, Joel R Lexchin
The costs of coronavirus vaccines and their pricing. Journal of the Royal Society of Medicine 114 (11) (2021)
Barbara J Mintzes, Alice L Bhasale, Marc Torka, Ruth Lopert, Sallie-Anne Pearson, Joel R Lexchin, Lisa A Bero
A sorry tale of unnecessary secrecy about medicine safety. Internal medicine journal 51 (10) (2021)
Joel R Lexchin
Time to market for drugs approved in Canada between 2014 and 2018: an observational study. BMJ open 11 (7) (2021)
Joel R Lexchin
Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada. International journal of health policy and management (2021)
Joel R Lexchin
A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study. Journal of pharmaceutical policy and practice 14 (1) (2021)
Alain Braillon, Susan Bewley, Aubrey Blumsohn, Florian Naudet, Jean-Louis Montastruc, Joel R Lexchin
Antidepressants are not safe during pregnancy and in women of child-bearing age. British journal of clinical pharmacology 88 (5) (2021)
Joel R Lexchin
How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study. PloS one 15 (11) (2020)
Joel R Lexchin
Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study. International journal of health policy and management (2020)
Lucy T Perry, Alice L Bhasale, Alice Fabbri, Joel R Lexchin, Lorri Puil, Maisah Joarder, Barbara J Mintzes
A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016. Pharmacoepidemiology and drug safety 29 (9) (2020)
Alice L Bhasale, Ameet Sarpatwari, Marie Louise De Bruin, Joel R Lexchin, Ruth Lopert, Priya Bahri, Barbara J Mintzes
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical pharmacology and therapeutics 109 (6) (2020)
Joel R Lexchin
Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic? Expert opinion on drug discovery 16 (5) (2020)
Dion Diep, Abnoos Mosleh-Shirazi, Joel R Lexchin
Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study. BMJ open 10 (7) (2020)
Joel R Lexchin, Nicolas Rasmussen
The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946-1990. International journal of health services : planning, administration, evaluation 50 (3) (2020)
Kimberly Turner, Andrea Carboni-Jiménez, Carla Benea, Katharine Elder, Brooke Levis, Jill Boruff, Michelle Roseman, Lisa Bero, Joel R Lexchin, Erick H Turner, Andrea Benedetti, Brett D Thombs
Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ open 10 (5) (2020)
Joel R Lexchin, Janice Graham, Matthew Herder, Tom Jefferson, Trudo Lemmens
Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. International journal of health services : planning, administration, evaluation 51 (1) (2020)
Joel R Lexchin
Drug Promotion in India Since 2000: Problems Remain. International journal of health services : planning, administration, evaluation 51 (3) (2020)
Joel R Lexchin
It's Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada". International journal of health policy and management 9 (12) (2020)
Joel R Lexchin
COVID-19: still much to learn. Journal of the Royal Society of Medicine 113 (7) (2020)
Joel R Lexchin
Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study. PloS one 14 (2) (2019)
Joel R Lexchin, Nicholas Moroz
Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia. International journal of health services : planning, administration, evaluation 50 (2) (2019)
Joel R Lexchin
Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study. BMJ open 9 (7) (2019)
Joel R Lexchin
Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study. Healthcare policy = Politiques de sante 14 (3) (2019)
Alain Braillon, Joel R Lexchin
Innovation and off-label use, the French case and more. British journal of clinical pharmacology 85 (10) (2019)
Teresa Leonardo Alves, Joel R Lexchin, Barbara J Mintzes
Medicines Information and the Regulation of the Promotion of Pharmaceuticals. Science and engineering ethics 25 (4) (2018)
Joel R Lexchin
Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study. BMJ open 8 (4) (2018)
Joel R Lexchin
Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis. BMJ open 8 (8) (2018)
Joel R Lexchin
Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis. Journal of pharmaceutical policy and practice 11 (2018)
Joel R Lexchin
Medicines Save, Medicines Kill. Drug safety 40 (6) (2018)
Roojin Habibi, Joel R Lexchin, Barbara Mintzes, Anne Holbrook
Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately? British journal of clinical pharmacology 83 (11) (2017)
Joel R Lexchin
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis. BMJ open 7 (10) (2017)

Joel R Lexchin.css-eqlu8i{font-size:small;padding-left:4px;} (Joel Lexchin)

Publication Activity (10 Years)

Top Topics

Top Venues

Joel R Lexchin (Joel Lexchin)